BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Biotechnology

Healthcare
$61.43 -0.18%

-$0.10 today

Market cap
$11.90B
Beta
0.24
P/E (TTM)
39.4
EPS (TTM)
$1.40
52W Low $49.26High $66.28

Volume 3.07M

Average 2.04M

BMRN Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

BioMarin Pharmaceutical Inc.NASDAQ: BMRN

Weighted Avg Shares (Diluted) · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q3 FY2026 weighted avg shares (diluted) of 193.59M shares rose 0.8% year over year, ahead of the +0.1% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it fell 0.3% from the prior quarter. Over 3 fiscal years it compounded at +1.5% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +0.8% holds above the trailing-twelve-month pace of +0.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
193.59M-0.3% QoQ
Last fiscal yearDec 2025
197.39M+0.3% YoY
LTMSep 2026
195.7M+0.1% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.8%——
1 year+0.3%——
3-year CAGR+1.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
197.39M USD
Year-over-year change
+0.3%
4-year CAGR
+1.9%

Weighted Avg Shares (Diluted) vs competitors

How BMRN compares with its peers on the latest reported figures

  • BMRN's LTM Sep 2026 weighted avg shares (diluted) of 195.7M shares is the 3rd highest of the 11 companies compared; the peer median is 118.6M shares.
  • Its year-over-year change of +0.1% is the 8th highest of 11, against a peer median of +4.5%.
  • Over three fiscal years its annual growth of +1.5% compares with a peer median of +5.6%.
BMRN Competitors Peer median
Weighted Avg Shares (Diluted) for BMRN and competitors
Company Period LTM YoY 3-year CAGR
VRTXVertex Pharmaceuticals IncorporatedLTM Sep 2026255.83M -1.3%-0.1%
INSMInsmed IncorporatedLTM Jun 2026214.47M +18.7%+20.2%
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026195.7M +0.1%+1.5%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026194.58M +2.6%+10.2%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026164.62M -0.2%+4.1%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026137.53M +6.5%+3.4%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 202699.68M +6.6%+12.1%
TVTXTravere Therapeutics, Inc.LTM Sep 202692.57M +2.0%+11.8%
PTCTPTC Therapeutics, Inc.LTM Jun 202685.59M +7.4%+7.2%
PHARPharming Group N.V.LTM Mar 202669.93M -1.6%-5.4%
ASNDAscendis Pharma A/SLTM Sep 202665.73M +7.4%+2.6%
Peer median (excluding BMRN) 118.6M+4.5%+5.6%

Competitors are the stored peer set for BMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.85B2.1B2.42B2.85B3.22B
Cost of Revenue470.52M503.02M532.06M580.24M736.83M
Gross Profit1.38B1.59B1.89B2.27B2.48B
Gross Margin74.5%76.0%78.0%79.7%77.1%
Research & Development628.79M649.61M746.77M747.18M921.93M
Selling, General & Admin759.4M823.2M892.4M1.01B1.28B
Operating Expenses1.46B1.43B1.7B1.79B1.95B
Depreciation & Amortization108.04M101.97M104.39M96.43M79.56M
EBITDA47.43M265.36M306.77M650.53M572.94M
EBITDA Margin2.6%12.7%12.7%22.8%17.8%
Operating Income(82.34M)160.97M185.77M484.21M533.48M
Operating Margin-4.5%7.7%7.7%17.0%16.6%
Interest Income10.48M18.03M58.34M74.88M74.9M
Interest Expense15.34M15.97M17.34M12.67M10.9M
Other Income / Expenses6.99M(11.4M)2.79M57.55M(51M)
Income Before Tax(75.35M)149.58M188.56M541.76M482.48M
Pre-Tax Margin-4.1%7.1%7.8%19.0%15.0%
Income Tax Expense(11.27M)8.02M20.92M114.9M133.58M
Net Income(64.08M)141.56M167.65M426.86M348.9M
Net Margin-3.5%6.8%6.9%15.0%10.8%
EPS (Basic)(0.35)0.760.892.251.82
EPS (Diluted)(0.35)0.750.882.211.80
Weighted Avg Shares182.85M185.27M187.83M190.03M191.79M
Weighted Avg Shares (Diluted)182.85M188.96M191.6M196.71M197.39M

BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Intrinsic Alpha fair value

Locked

Current Price

$61.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.